OS Therapies Incorporated (OSTX)
| Market Cap | 60.07M -4.2% |
| Revenue (ttm) | n/a |
| Net Income | -39.37M |
| EPS | -1.05 |
| Shares Out | 46.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 375,157 |
| Open | 1.250 |
| Previous Close | 1.250 |
| Day's Range | 1.250 - 1.330 |
| 52-Week Range | 1.150 - 2.250 |
| Beta | -0.64 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+553.85%) |
| Est. Earnings | Nov 16, 2026 |
About OSTX
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company’s pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and i... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for OSTX stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 553.85% from the latest price.
News
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million
Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestones Company expects to complete early marke...
Rubenstein Public Relations Named Agency of Record for OS Therapies
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rubenstein Public Relations (RPR), a leading full-service communications firm, announces it has been named the Agency of Record for OS Therapies, Inc. (NY...
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
Received notice for upcoming USDA meeting Company is reviewing strategic alternatives to monetize OS Animal Health ("OSAH") Grasonville, Maryland--(Newsfile Corp. - October 7, 2026) - OS Therapies, In...
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients 72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p...
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate Herlystic™(OST-HER2; daznelimgene lisbac) Grasonville, Maryl...
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeri...
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing A...
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
FDA aligns with MHRA and EMA on adaptive design for Phase 3 trial After successful Scientific Advice Meeting, Company accepts MHRA request to become he Company's' sponsor into Project Orbis to harmoni...
OS Therapies announces full alignment on UK authorization application
OS Therapies (OSTX) announced that it has achieved full alignment with the U.K. Medicines and Healthcare products Regulatory Agency on its pending conditional marketing authorization application. MHRA...
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissions Full alignment achieved on confirmatory Phase 3 trial design Complete CMAA submission expected in ...
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002) The two remaining patients who have not yet reached the 3-year timepoint from e...
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development adviso...
OS Therapies Slides: Company presentation
OS Therapies has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closing FDA Type C Statistical Meth...
OS Therapies Quarterly report: Q2 2026
OS Therapies has published its Q2 2026 quarterly earnings report on August 14, 2026.
OS Therapies Earnings release: Q2 2026
OS Therapies released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September, 2026 Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designa...
OS Therapies terminates At Market Issuance Sales Agreement
In a filing, OS Therapies (OSTX) disclosed that on July 23, it delivered to B. Riley Securities and JonesTrading Institutional Services written notice of termination of the At Market Issuance…
OS Therapies Proxy statement: Proxy filing
OS Therapies filed a proxy statement on July 24, 2026, providing details for shareholder voting and corporate governance matters.
OS Therapies Proxy statement: Proxy filing
OS Therapies filed a proxy statement on July 24, 2026, providing details for shareholder voting and corporate governance matters.
OS Therapies initiated with a Buy at Roth Capital
Roth Capital analyst Adam Walsh initiated coverage of OS Therapies (OSTX) with a Buy rating and $7 price target The firm believes Listeria immunotherapy OST-HER2 “works” and approval is “more…
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
CDER meeting expected to take place in the summer of 2026 in parallel with CBER's Type B Statistical Methods Meeting New York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Th...
OS Therapies Third Quarter 2026 Corporate Outlook
Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market a...
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
Company secures $10 million line of credit supported by OS Therapies UK tax credits New York, New York and Rockville, Maryland--(Newsfile Corp. - July 2, 2026) - OS Therapies, Inc. (NYSE American: OST...
OS Therapies Provides U.S. Regulatory Update
Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods to be used for BLA Submission Seeking to align FDA with MHRA & EMA on 3-year overall ...